Neural Therapeutics Inc.
NURL
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -137.11% | 118.14% | -747.48% | -10.58% | 51.74% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.39% | -124.04% | 9,198.11% | -191.38% | 1.75% |
| Change in Net Operating Assets | 150.46% | -315.03% | -81.23% | 21.28% | -48.51% |
| Cash from Operations | -54.89% | 87.84% | -3,615.38% | -642.86% | 95.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -200.00% | -- | -- |
| Total Debt Repaid | -- | 95.97% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -87.62% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -- | -1,053.66% | -98.74% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.85% | 66.88% | -159.12% | 45,771.43% | -102.22% |